Soleno Therapeutics Inc (SLNO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Soleno Therapeutics Inc (SLNO) has a cash flow conversion efficiency ratio of 0.052x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($25.98 Million) by net assets ($495.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Soleno Therapeutics Inc defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Soleno Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Soleno Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Soleno Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Soleno Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
IHS Holding Ltd
NYSE:IHS
|
-8.679x |
|
Apeloa Pharmaceutical Co Ltd
SHE:000739
|
0.068x |
|
ChengDu Hi-Tech Development Co Ltd
SHE:000628
|
0.041x |
|
Northeast Securities Co Ltd
SHE:000686
|
0.322x |
|
Treasury Wine Estates Ltd
AU:TWE
|
0.030x |
|
Steadfast Group Limited
F:1S6
|
0.055x |
|
HMS Networks AB (publ)
ST:HMS
|
0.067x |
|
Bangkok Expressway and Metro Public Company Limited
BK:BEM
|
-0.168x |
Annual Cash Flow Conversion Efficiency for Soleno Therapeutics Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Soleno Therapeutics Inc from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Soleno Therapeutics Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $450.12 Million | $46.80 Million | 0.104x | +136.88% |
| 2024-12-31 | $245.11 Million | $-69.10 Million | -0.282x | -78.03% |
| 2023-12-31 | $157.51 Million | $-24.94 Million | -0.158x | +92.12% |
| 2022-12-31 | $10.35 Million | $-20.78 Million | -2.008x | -28.67% |
| 2021-12-31 | $17.79 Million | $-27.77 Million | -1.561x | -181.82% |
| 2020-12-31 | $45.55 Million | $-25.22 Million | -0.554x | +52.36% |
| 2019-12-31 | $14.95 Million | $-17.38 Million | -1.162x | -202.60% |
| 2018-12-31 | $30.41 Million | $-11.68 Million | -0.384x | -2.45% |
| 2017-12-31 | $26.53 Million | $-9.95 Million | -0.375x | +90.46% |
| 2016-12-31 | $3.44 Million | $-13.50 Million | -3.929x | -22.99% |
| 2015-12-31 | $3.22 Million | $-10.30 Million | -3.195x | -836.12% |
| 2014-12-31 | $-10.33 Million | $-4.48 Million | 0.434x | +1756.41% |
| 2013-12-31 | $-37.86 Million | $-885.22K | 0.023x | -77.14% |
| 2012-12-31 | $-34.20 Million | $-3.50 Million | 0.102x | -- |
About Soleno Therapeutics Inc
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeut… Read more